Burn sepsis and burn toxin.
The salient steps of a 20-year programme of research into the nature of burn disease are described. By burn disease we mean the late mortality and morbidity following burns. We have isolated a burn toxin which is derived from a thermal polymerization of cell membrane lipoproteins within the dermis and have studied its influence on the effects of sepsis. We have also used it in the development of active and passive immunization therapy of severe burns.
D000818:Animals; D000992:Antitoxins / Q000627:therapeutic use; D002056:Burns / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D002473:Cell Wall / Q000032:analysis; D002850:Chromatography, Gel; D002855:Chromatography, Thin Layer; D004589:Electrophoresis, Disc; D006706:Homeostasis; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000627:therapeutic use; D008074:Lipoproteins / Q000302:isolation & purification; D051379:Mice; D008854:Microscopy, Electron; D008970:Molecular Weight; D011552:Pseudomonas Infections / Q000150:complications; D018805:Sepsis / Q000150:complications*; D012867:Skin / Q000032:analysis*; D012881:Skin Temperature; D014118:Toxins, Biological / Q000302:isolation & purification*; D014461:Ultracentrifugation
D000992:Antitoxins; D007074:Immunoglobulin G; D008074:Lipoproteins; D014118:Toxins, Biological